Legend Biotech
LEGN
71 hedge funds and large institutions have $767M invested in Legend Biotech in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 12 closing their positions.
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
16% more funds holding
Funds holding: 61 → 71 (+10)
6% more capital invested
Capital invested by funds: $723M → $767M (+$43.8M)
0.36% more ownership
Funds ownership: 9.65% → 10.01% (+0.36%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
69% less call options, than puts
Call options by funds: $263K | Put options by funds: $836K
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$44.7M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$24.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$24.3M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$23M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$11.2M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MS
76
Maven Securities
St Helier,
Jersey
| – | -$1.08M | -36,741 | Closed |
|
|
PA
77
Perceptive Advisors
New York
| – | -$704K | -25,000 | Closed |
|
78
TD Asset Management
Toronto,
Ontario, Canada
| – | -$454K | -16,127 | Closed |
|
|
CSS
79
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$271K | -9,639 | Closed |
|
|
AC
80
Athanor Capital
New York
| – | -$235K | -8,329 | Closed |
|
81
Arrowstreet Capital
Boston,
Massachusetts
| – | -$233K | -8,279 | Closed |
|
|
SOW
82
State of Wyoming
Cheyenne,
Wyoming
| – | +$136 | +5 | New |
|
83
Simplex Trading
Chicago,
Illinois
| – | +$518 | +19 | New |
|
LEGN Hedge Fund Activity: Q1 2021 in Review
71 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q1 2021, worth a combined $767M — up 6.1% from $723M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LEGN positions and 12 closed out — a net gain of 10 holders — while 20 added to existing stakes and 13 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $44.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $67.8M sold.
- 71 institutional investors held Legend Biotech (LEGN) as of Q1 2021, up from 61 in Q4 2020.
- Funds reported $767M of Legend Biotech stock for Q1 2021, up 6.1% quarter-over-quarter.
- 22 funds opened new Legend Biotech positions in Q1 2021 and 12 closed out, a net change of +10 holders.
- The largest Legend Biotech buyer in Q1 2021 was Point72 Asset Management, an estimated $44.7M added.
- The largest Legend Biotech seller in Q1 2021 was RA Capital Management, an estimated $67.8M sold.
Based on aggregated 13F filings for Q1 2021.